- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06076005
Lung Cancer ID (Identity) Study
April 4, 2024 updated by: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Demographic, Clinical, Histological and Molecular Characteristics of Advanced LUNG CANCER at the tIme of Diagnosis in a Large Italian Cohort: an Observational Cohort Study: Lung Cancer ID Study
The distribution of demographic, clinical, radiological, pathological and molecular characteristics of lung cancer at the time of diagnosis, as well as preferential association between elements of those domains, have not been specifically studied in Italy.
The aim of the present project is to assess, in a systematic fashion, the demographic, clinical, radiological, pathological and molecular characteristics of advanced lung cancer at the time of diagnosis in a large Italian cohort of consecutive patients referred to two tertiary referral centers.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
1000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Rocco Trisolini, MD
- Phone Number: 0630154163
- Email: rocco.trisolini@policlinicogemelli.it
Study Locations
-
-
-
Roma, Italy
- Not yet recruiting
- Istituto Nazionale Tumori Regina Elena
-
Contact:
- Federico Cappuzzo, MD
-
Roma, Italy
- Recruiting
- Interventional Pulmonology Division - Fondazione Policlinico Universitario A. Gemelli IRCCS
-
Contact:
- Marta Viscuso, MD
- Email: marta.viscuso@guest.policlinicogemelli.it
-
Roma, Italy
- Not yet recruiting
- Medical Oncology Division - Fondazione Policlinico Universitario Agostino Gemelli IRCCS
-
Contact:
- Emilio Bria
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
N/A
Sampling Method
Probability Sample
Study Population
Consecutive, treatment-naïve, patients with clinical and radiological suspicion of advanced lung cancer referred for the initial diagnosis/staging/molecular profiling.
Description
Inclusion Criteria:
- Age >18 years
- Suspicion of lung cancer based on imaging (CT and/or PET/CT)
- Indication to a biopsy for diagnosis, staging and/or molecular profiling
Exclusion Criteria:
- Inability or unwillingness to provide a written informed consent
- ECOG performance status (>3) which makes a tissue diagnosis unfeasible
- ASA 4 status
- TNM Stage I-III
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Distribution of histologic subtypes
Time Frame: 24 months
|
The investigators will assess the prevalence of histologic subtypes in patients with advanced lung cancer
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Molecular profiling
Time Frame: 24 months
|
Prevalence of individual molecular markers in patients with advanced non-squamous non-small cell lung cancer histology
|
24 months
|
Time to diagnosis
Time Frame: 24 months
|
Time lag between onset of symptoms (if any) and invasive testing
|
24 months
|
Distribution of histologic subtypes according to clinical and radiological characteristics
Time Frame: 24 months
|
The investigators will assess the prevalence of different histologic subtypes according to clinical and imaging characteristics
|
24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2023
Primary Completion (Estimated)
June 30, 2025
Study Completion (Estimated)
October 31, 2025
Study Registration Dates
First Submitted
October 4, 2023
First Submitted That Met QC Criteria
October 4, 2023
First Posted (Actual)
October 10, 2023
Study Record Updates
Last Update Posted (Actual)
April 5, 2024
Last Update Submitted That Met QC Criteria
April 4, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 5937
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
IPD Plan Description
The investigators will decide how to share the data at the end of the study upon reasonable request to be addressed to the principal investigator.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Cancer Stage IV
-
Jerome Canady, M.D.Active, not recruitingStage IV Lung Cancer | Stage IV Bladder Cancer | Stage IV Pancreatic Cancer | Recurrent Malignant Solid Neoplasm | Stage IV Breast Cancer | Stage IV Renal Cell Cancer | Stage IV Prostate Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer | Stage IV Gastric Cancer | Stage IV Non-small Cell Lung Cancer | Stage... and other conditionsUnited States
-
Vestre Viken Hospital TrustOdense University Hospital; Karolinska University Hospital; Oslo University Hospital and other collaboratorsRecruitingCancer | Lung Cancer | NSCLC Stage IV | Mutation | NSCLC, Stage III | Lung Cancer Stage IV | Cancer, LungNorway
-
Seoul National University HospitalNational Cancer Center, Korea; Chonbuk National University Hospital; Asan Medical... and other collaboratorsCompletedStage IV Lung Cancer | Stage IV Pancreatic Cancer | Stage IV Breast Cancer | Pediatric Brain Tumor | Stage IV Colon Cancer | Stage IV Gastric Cancer | Stage IV Liver Cancer | Malignant Hematologic Neoplasm | Pediatric Solid Tumor | Pediatric Lymphoma | Biliary Cancer Metastatic | Pediatric LeukemiaKorea, Republic of
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)CompletedStage IV Lung Cancer | Stage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Malignant Female Reproductive System Neoplasm | Stage III... and other conditionsUnited States
-
Holy Cross Hospital, MarylandWithdrawn
-
Biomea Fusion Inc.RecruitingColorectal Cancer | Pancreatic Cancer | NSCLC | Non Small Cell Lung Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | CRC | KRAS Mutation-Related Tumors | Relapsed Cancer | Refractory Cancer | Stage IV Non-small Cell Lung Cancer | Stage IV Colorectal Cancer | Stage III Non-small Cell Lung Cancer | Stage III NSCLC and other conditionsUnited States, Korea, Republic of
-
Washington University School of MedicineWashington University Department of Psychological and Brain SciencesTerminatedStage III Gynecologic Cancer | Stage IV Gynecologic CancerUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)Not yet recruitingStage IV Lung Cancer | Stage III Lung Cancer | Stage II Lung Cancer
-
Maastricht Radiation OncologyAmsterdam UMC, location VUmcCompleted
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Metastatic Breast CarcinomaUnited States
Clinical Trials on Advanced lung cancer patients' group
-
University of GiessenRecruitingPulmonary Hypertension Due to Lung Diseases and HypoxiaGermany
-
Institut CurieRecruiting
-
Duke UniversityNational Institutes of Health (NIH)CompletedLung Cancer Stage III | Lung Cancer Stage IVUnited States
-
Radiotherapy Oncology Centre "Santa Maria" HospitalPaola Anselmo,MD; Michelina Casale,PhD; Ernesto Maranzano,MD; Fabio Trippa,MDCompletedLocally Advanced Lung Non-Small Cell CarcinomaItaly
-
Duke UniversityWake Forest University Health SciencesCompletedLung Cancer Stage III | Lung Cancer Stage IVUnited States
-
Guangdong Provincial People's HospitalUnknownLung Neoplasms | Venous ThromboembolismChina
-
Peking University People's HospitalUnknown
-
Peking University Third HospitalCompletedParaneoplastic Neurological SyndromeChina
-
National Health Research Institutes, TaiwanRecruiting
-
Sun Yat-sen UniversityGuangzhou Yiyang Biological Technology Co., Ltd.Terminated